Gilead to reveal pivotal liver disease research
Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis
Read Moreby John Pinching | Jun 14, 2023 | News | 0
Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis
Read Moreby John Pinching | May 15, 2023 | News | 0
NICE’s decision will result in eligible patients using a treatment that slows or halts aspects of the illness
Read Moreby John Pinching | May 9, 2023 | News | 0
The therapy treats adults with chronic hepatitis delta virus and compensated liver disease
Read Moreby John Pinching | May 5, 2023 | News | 0
The vital recommendation ensures marketing authorisation for treating the hepatitis delta virus
Read Moreby John Pinching | Jan 26, 2023 | News | 0
Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Read Moreby John Pinching | Nov 2, 2022 | News | 0
The study evaluated the safety, efficacy and immunogenicity of AELIX’s HIV vaccine
Read Moreby John Pinching | Jun 8, 2022 | News | 0
The companies have partnered for a second time to support sector-wide efforts to eliminate hepatitis C virus in drug and alcohol services
Read Moreby John Pinching | Apr 6, 2022 | News | 0
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
Read Moreby Lucy Parsons | Oct 29, 2021 | News | 0
The companies will evaluate Trodelvy plus Keytruda for the first-line treatment of certain triple-negative breast cancer patients
Read Moreby Lucy Parsons | Jun 30, 2021 | News | 0
Lenacapavir is designed to inhibit HIV-1 replication by interfering with a number of ‘essential’ steps in the viral lifecycle
Read Moreby Lucy Parsons | Jun 24, 2021 | News | 0
Preparations come on the heels of positive results from the Phase II ARC-7 study
Read Moreby Lucy Parsons | May 19, 2021 | News | 0
The Cell & Gene Collective is aiming to advocate for the adoption of next-generation medicine in the UK
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479